Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 106 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Atezolizumab in addition to chemotherapy for small cell lung cancer – first line	Atezolizumab (Tecentriq; MPDL3280A)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2018	View \| Download
Atezolizumab in addition to chemotherapy for stage IV non-squamous non-small-cell lung cancer – first line	Atezolizumab (Tecentriq; MPDL3280A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
Atezolizumab in Addition to Chemotherapy for Stage IV Squamous Non-Small Cell Lung Cancer – First Line	Atezolizumab (Tecentriq; MPDL3280A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
Atezolizumab in combination with chemotherapy for non-small-cell lung cancer- neoadjuvant and adjuvant	Atezolizumab (Tecentriq; MPDL3280A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-containing chemotherapy and one programmed death-ligand 1 checkpoint inhibitor	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Avatrombopag for chemotherapy induced thrombocytopenia in patients with nonhaematological cancers	Avatrombopag (Doptelet; E5501; avatrombopag maleate)	Chemotherapy-induced thrombocytopenia	Female Reproductive Cancer , Haematology , Lung and Respiratory Cancer , Toxicology , Urological Cancer	2020	View \| Download
Brigatinib (Alunbrig) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer	Brigatinib (Alunbrig; AP26113)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Brigatinib for ALK-positive, locally advanced or metastatic, non-small cell lung cancer previously treated with alectinib or ceritinib	Brigatinib (Alunbrig; AP26113)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2019	View \| Download
Brigatinib for locally advanced or metastatic, ALK-positive, non-small cell lung cancer – first line	Brigatinib (Alunbrig; AP26113)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
BV-NSCLC- 002 (Cimavax) for non-small-cell lung cancer wild type EGF receptor positive patients	EGF-PTI (CimaVax)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download